» Articles » PMID: 23599930

Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic

Overview
Journal JAMA Neurol
Date 2013 Apr 20
PMID 23599930
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the reliability of new magnetic resonance imaging (MRI) lesion counts by clinicians in a multiple sclerosis specialty clinic.

Design: An observational study.

Setting: A multiple sclerosis specialty clinic.

Patients: Eighty-five patients with multiple sclerosis participating in a National Institutes of Health–supported longitudinal study were included.

Intervention: Each patient had a brain MRI scan at entry and 6 months later using a standardized protocol.

Main Outcome Measures: The number of new T2 lesions, newly enlarging T2 lesions, and gadolinium-enhancing lesions were measured on the 6-month MRI using a computer-based image analysis program for the original study. For this study, images were reanalyzed by an expert neuroradiologist and 3 clinician raters. The neuroradiologist evaluated the original image pairs; the clinicians evaluated image pairs that were modified to simulate clinical practice. New lesion counts were compared across raters, as was classification of patients as MRI active or inactive.

Results: Agreement on lesion counts was highest for gadolinium-enhancing lesions, intermediate for new T2 lesions, and poor for enlarging T2 lesions. In 18% to 25% of the cases, MRI activity was classified differently by the clinician raters compared with the neuroradiologist or computer program. Variability among the clinical raters for estimates of new T2 lesions was affected most strongly by the image modifications that simulated low image quality and different head position.

Conclusions: Between-rater variability in new T2 lesion counts may be reduced by improved standardization of image acquisitions, but this approach may not be practical in most clinical environments. Ultimately, more reliable, robust, and accessible image analysis methods are needed for accurate multiple sclerosis disease-modifying drug monitoring and decision making in the routine clinic setting.

Citing Articles

Lifestyle management and brain MRI metrics in female Australian adults living with multiple sclerosis: a feasibility and acceptability study.

Wills O, Wright B, Greenwood L, Solowij N, Schira M, Maller J Pilot Feasibility Stud. 2024; 10(1):71.

PMID: 38698454 PMC: 11064336. DOI: 10.1186/s40814-024-01495-3.


A unified framework for focal intensity change detection and deformable image registration. Application to the monitoring of multiple sclerosis lesions in longitudinal 3D brain MRI.

Dufresne E, Fortun D, Kremer S, Noblet V Front Neuroimaging. 2023; 1:1008128.

PMID: 37555167 PMC: 10406299. DOI: 10.3389/fnimg.2022.1008128.


Scanner agnostic large-scale evaluation of MS lesion delineation tool for clinical MRI.

Hindsholm A, Andersen F, Cramer S, Simonsen H, Asklof M, Magyari M Front Neurosci. 2023; 17:1177540.

PMID: 37274207 PMC: 10235534. DOI: 10.3389/fnins.2023.1177540.


Improving the detection of new lesions in multiple sclerosis with a cascaded 3D fully convolutional neural network approach.

Salem M, Ryan M, Oliver A, Hussain K, Llado X Front Neurosci. 2022; 16:1007619.

PMID: 36507318 PMC: 9730806. DOI: 10.3389/fnins.2022.1007619.


Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population.

Simonsen C, Flemmen H, Broch L, Brekke K, Brunborg C, Berg-Hansen P Front Neurol. 2022; 13:1034056.

PMID: 36452173 PMC: 9702815. DOI: 10.3389/fneur.2022.1034056.


References
1.
Rudick R, Lee J, Simon J, Ransohoff R, Fisher E . Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004; 56(4):548-55. DOI: 10.1002/ana.20224. View

2.
Filippi M, Barkhof F, Bressi S, Yousry T, Miller D . Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis. Mult Scler. 1997; 3(4):226-30. DOI: 10.1177/135245859700300402. View

3.
Filippi M, Horsfield M, Tofts P, Barkhof F, Thompson A, Miller D . Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain. 1995; 118 ( Pt 6):1601-12. DOI: 10.1093/brain/118.6.1601. View

4.
Brex P, Ciccarelli O, ORiordan J, Sailer M, Thompson A, Miller D . A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002; 346(3):158-64. DOI: 10.1056/NEJMoa011341. View

5.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P . A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):416-26. DOI: 10.1056/NEJMoa0902533. View